Summary: PLT Health Solutions has launched Vanizem, a botanical ingredient derived from the Aframomum melegueta plant, which has been clinically demonstrated to reduce stress, enhance mood, and improve sleep quality. The ingredient, introduced to European markets earlier this year, showed improvements in sleep and mood metrics in a recent clinical trial, with noticeable benefits observed within three days at a low dose. Vanizem aims to provide a versatile option for consumer products targeting cognitive health and sleep enhancement.
Key Takeaways:
- Results: Vanizem has been clinically proven to improve mood, reduce stress, and enhance sleep quality within three days at a low dose.
- Versatile Application: The ingredient offers potential for a range of consumer products targeting stress relief, mood enhancement, and improved sleep, according to PLT Health Solution.
- Clinical Validation: Derived from the Aframomum melegueta plant, Vanizem demonstrated improvements in self-reported tension scores, sleep quality, and overall well-being in clinical trials.
PLT Health Solutions is adding to its cognitive health portfolio in North America with the launch of Vanizem, a botanical ingredient that has been clinically demonstrated to reduce stress, enhance mood and happiness, and improve sleep and waking outcomes.
Vanizem is a proprietary selection and extraction of the West African flowering plant Aframomum melegueta (Grains of Paradise) with standardized bioactives. In a recently completed clinical study, Vanizem was shown to provide improvements in self-reported tension scores and significant improvements in sleep quality score, along with improvements in mood, vigor, ease of falling asleep, and easier morning awakening.
The ingredient was introduced to European markets by PLT innovation partner Nektium Pharma (Las Palmas, Spain) in March. PLT Health Solutions is the exclusive sales and marketing partner for Vanizem in North America.
Subjects taking Vanizem in the clinical trial saw statistically significant improvements at three days with a low dose, according to the company.
According to Jennifer Murphy, MS, RD, director of innovation and clinical development for PLT Health Solutions, Vanizem can help companies develop a range of consumer products. “The clinical data on Vanizem shows that it can enhance formulations targeting stress and mood as well as those designed to promote and improve sleep. The effects on sleep are especially remarkable, given subjects took it early in the day. This speaks to Vanizem’s powerful impact on stress and tension,” she says in a release.
These statements have not been evaluated by the US Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Photo 304457513 | Aframomum Melegueta Plant © Robert Buchel | Dreamstime.com
Leave a Reply